Trientine Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Trientine comprises 18 peer-reviewed publications across 14 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hepatolenticular Degeneration, Carcinoma, Ovarian Epithelial, Neoplasm Metastasis, and Cardiomyopathy, Hypertrophic. Most recent publication: Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease., JGH Open, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.
    Weiss KH, Kruse C, Manolaki N, et al. · Eur J Gastroenterol Hepatol · 2022
    PubMed: PMID 35482910 · NCT02426905 · Hepatolenticular Degeneration
  2. Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease.
    Mohr I, Kruse C, Aliane V, et al. · JGH Open · 2025
    PubMed: PMID 40104015 · NCT02426905 · Hepatolenticular Degeneration
  3. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.
    Huang YF, Kuo MT, Liu YS, et al. · Front Oncol · 2020
    PubMed: PMID 31179244 · NCT03480750 (Trientine) · Carcinoma, Ovarian Epithelial
  4. Overcoming platinum resistance through the use of a copper-lowering agent.
    Fu S, Naing A, Fu C, et al. · Mol Cancer Ther · 2013
    PubMed: PMID 22491798 · NCT01178112 · Neoplasm Metastasis
  5. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
    Farrant J, Dodd S, Vaughan C, et al. · Heart · 2023
    PubMed: PMID 37137675 · NCT04706429 (TEMPEST) · Cardiomyopathy, Hypertrophic
  6. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.
    Ala A, Aliu E, Schilsky ML, et al. · Dig Dis Sci · 2015
    PubMed: PMID 25605552 · NCT01472874 · Hepatolenticular Degeneration
  7. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
    Walshe JM · Lancet · 1982
    PubMed: PMID 6121964 · NCT01472874 · Hepatolenticular Degeneration
  8. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
    Scheinberg IH, Jaffe ME, Sternlieb I, et al. · N Engl J Med · 1987
    PubMed: PMID 3600712 · NCT01472874 · Hepatolenticular Degeneration

Publications by year

1982–2025: 18 publications.

1982
1
1987
1
1994
2
1996
1
2001
2
2003
2
2004
1
2006
2
2013
1
2015
1
2020
1
2022
1
2023
1
2025
1

Publications by indication

Hepatolenticular Degeneration (15)

  • Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease.
    JGH Open · 2025 · PMID 40104015 · NCT02426905
  • Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.
    Eur J Gastroenterol Hepatol · 2022 · PMID 35482910 · NCT02426905
  • Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.
    Dig Dis Sci · 2015 · PMID 25605552 · NCT01472874
  • Wilson's Disease.
    Clin Gastroenterol Hepatol · 2006 · PMID 16233999 · NCT01472874
  • Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
    Arch Neurol · 2006 · PMID 16606763 · NCT01472874

Carcinoma, Ovarian Epithelial (1)

  • A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.
    Front Oncol · 2020 · PMID 31179244 · NCT03480750

Neoplasm Metastasis (1)

  • Overcoming platinum resistance through the use of a copper-lowering agent.
    Mol Cancer Ther · 2013 · PMID 22491798 · NCT01178112

Cardiomyopathy, Hypertrophic (1)

  • Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
    Heart · 2023 · PMID 37137675 · NCT04706429

Publications by journal

  • Arch Neurol3 papers
  • Hepatology2 papers
  • J Lab Clin Med2 papers
  • Eur J Gastroenterol Hepatol1 paper
  • JGH Open1 paper
  • Front Oncol1 paper
  • Mol Cancer Ther1 paper
  • Heart1 paper
  • Dig Dis Sci1 paper
  • Lancet1 paper

All Trientine publications (18)

2025 (1 paper)

  1. Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease.
    Mohr I, Kruse C, Aliane V, et al. · JGH Open · 2025 · Derived
    PubMed: PMID 40104015 · NCT02426905 · Hepatolenticular Degeneration

2023 (1 paper)

  1. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
    Farrant J, Dodd S, Vaughan C, et al. · Heart · 2023 · Derived
    PubMed: PMID 37137675 · NCT04706429 (TEMPEST) · Cardiomyopathy, Hypertrophic

2022 (1 paper)

  1. Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.
    Weiss KH, Kruse C, Manolaki N, et al. · Eur J Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35482910 · NCT02426905 · Hepatolenticular Degeneration

2020 (1 paper)

  1. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.
    Huang YF, Kuo MT, Liu YS, et al. · Front Oncol · 2020 · Derived
    PubMed: PMID 31179244 · NCT03480750 (Trientine) · Carcinoma, Ovarian Epithelial

2015 (1 paper)

  1. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.
    Ala A, Aliu E, Schilsky ML, et al. · Dig Dis Sci · 2015 · Derived
    PubMed: PMID 25605552 · NCT01472874 · Hepatolenticular Degeneration

2013 (1 paper)

  1. Overcoming platinum resistance through the use of a copper-lowering agent.
    Fu S, Naing A, Fu C, et al. · Mol Cancer Ther · 2013 · Derived
    PubMed: PMID 22491798 · NCT01178112 · Neoplasm Metastasis

2006 (2 papers)

  1. Wilson's Disease.
    Ferenci P · Clin Gastroenterol Hepatol · 2006 · Background
    PubMed: PMID 16233999 · NCT01472874 · Hepatolenticular Degeneration
  2. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
    Brewer GJ, Askari F, Lorincz MT, et al. · Arch Neurol · 2006 · Background
    PubMed: PMID 16606763 · NCT01472874 · Hepatolenticular Degeneration

2004 (1 paper)

  1. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
    Askari FK, Greenson J, Dick RD, et al. · J Lab Clin Med · 2004 · Background
    PubMed: PMID 14713890 · NCT01472874 · Hepatolenticular Degeneration

2003 (2 papers)

  1. A practice guideline on Wilson disease.
    Roberts EA, Schilsky ML, Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada, et al. · Hepatology · 2003 · Background
    PubMed: PMID 12774027 · NCT01472874 · Hepatolenticular Degeneration
  2. Diagnosis and phenotypic classification of Wilson disease.
    Ferenci P, Caca K, Loudianos G, et al. · Liver Int · 2003 · Background
    PubMed: PMID 12955875 · NCT01472874 · Hepatolenticular Degeneration

2001 (2 papers)

  1. Orthotopic liver transplantation for Wilson's disease: a single-center experience.
    Emre S, Atillasoy EO, Ozdemir S, et al. · Transplantation · 2001 · Background
    PubMed: PMID 11602847 · NCT01472874 · Hepatolenticular Degeneration
  2. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years.
    Brewer GJ, Dick RD, Johnson VD, et al. · J Lab Clin Med · 2001 · Background
    PubMed: PMID 11241029 · NCT01472874 · Hepatolenticular Degeneration

1996 (1 paper)

  1. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
    Brewer GJ, Johnson V, Dick RD, et al. · Arch Neurol · 1996 · Background
    PubMed: PMID 8859064 · NCT00004339 · Hepatolenticular Degeneration

1994 (2 papers)

  1. Liver transplantation for Wilson's disease: indications and outcome.
    Schilsky ML, Scheinberg IH, Sternlieb I, et al. · Hepatology · 1994 · Background
    PubMed: PMID 8119682 · NCT01472874 · Hepatolenticular Degeneration
  2. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
    Brewer GJ, Dick RD, Johnson V, et al. · Arch Neurol · 1994 · Background
    PubMed: PMID 8198464 · NCT00004339 · Hepatolenticular Degeneration

1987 (1 paper)

  1. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
    Scheinberg IH, Jaffe ME, Sternlieb I, et al. · N Engl J Med · 1987 · Background
    PubMed: PMID 3600712 · NCT01472874 · Hepatolenticular Degeneration

1982 (1 paper)

  1. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
    Walshe JM · Lancet · 1982 · Background
    PubMed: PMID 6121964 · NCT01472874 · Hepatolenticular Degeneration

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Fri, 17 Jul 2026 04:02:37 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).